Danicamtiv
AssetAlso MYK-491, SAR-440181
Activates cardiac myosin to enhance heart muscle contraction.
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- MYH7
- 3
- Indications
- 3
- Trials
- 1
- Developer
Indications
3Dilated cardiomyopathy
Phase 3, Not yet recruiting, CTIS2026-526139-20-00, euclinicaltrials.eu, 10 Oct 2026
Symptomatic genetic and familial dilated cardiomyopathy.
Phase 3, Not yet recruiting, CTIS2026-526139-20-00, euclinicaltrials.eu, 10 Oct 2026
Symptomatic genetic dilated cardiomyopathy
Phase 3, Recruiting, NCT07771465, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Trials3
- Evidence for its targets1
- Competitors4
- Signals5
Every asset’s record: target, stage, trials and the evidence behind it.